Module

Evaluating Long-Term Safety of Aromatase Inhibitors

Source: Management of ER+ Postmenopausal Early Breast Cancer

Evaluating Long-Term Safety of Aromatase Inhibitors

Program Director: Paul E. Goss, MD, PhD, FRCPC, FRCP

Faculty:

Paul E. Goss, MD, PhD, FRCPC, FRCP

CME CREDIT INFORMATION

Release Date: 05/07/08

Expiration Date: 05/06/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the safety results of clinical trials using tamoxifen and aromatase inhibitors in the treatment of postmenopausal patients with estrogen receptor–positive breast cancer
Discuss the role of estrogen in the treatment and prevention of breast cancer
Cite the risks and benefits associated with endocrine therapies for breast cancer treatment
Recount the effects that aromatase inhibitors have on end organs

Topics covered include:

Introduction
AIs and Effects on Bone
AIs and Hot Flashes
AIs and Arthralgia
AIs and Cognitive Dysfunction
AIs and Coagulation Effects
AIs and Cardiovascular Effects
AIs and Gynecologic Effects
AIs and Quality of Life
Conclusion

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.